GLPG1837
( DrugBank: GLPG-1837 / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 299 | 嚢胞性線維症 | 8 |
299. 嚢胞性線維症
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
Showing 1 to 8 of 8 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-003291-77-DE (EUCTR) | 25/05/201620160525 | 11/11/201520151111 | A study looking at the safety of the drug GLPG1837 in patients with cystic fibrosis and the G551D mutation A study looking at the safety of the drug GLPG1837in patients with cystic fibrosis and the G551D mut ... | A phase IIa, open label study of multiple doses of GLPG1837 in subjects with cystic fibrosis and the G551D mutation A phase IIa, open label study of multiple doses of GLPG1837in subjects with cystic fibrosis and the ... | Cystic fibrosis with the G551D mutation MedDRA version: 19.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Cystic fibrosis with the G551D mutation MedDRA version: 19.0;Level: PT;Classification code 10011762; ... | Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive nam ... | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 32 | Phase 2 | Czech Republic;Ireland;Australia;Germany;United Kingdom | ||
| 2 | EUCTR2015-003292-30-NL (EUCTR) | 26/02/201620160226 | 02/12/201520151202 | A study looking at the safety of the drug GLPG1837 in patients with cysticfibrosis and the S1251N mutation A study looking at the safety of the drug GLPG1837in patients with cysticfibrosis and the S1251N mut ... | A phase IIa, open-label study of two doses of GLPG1837 in subjects with cystic fibrosis and the S1251N mutation. A phase IIa, open-label study of two doses of GLPG1837in subjects with cystic fibrosis and the S1251 ... | Cystic fibrosis with the S1251N mutation MedDRA version: 18.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Cystic fibrosis with the S1251N mutation MedDRA version: 18.1;Level: PT;Classification code 10011762 ... | Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive nam ... | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 6 | Phase 2 | Belgium;Netherlands | ||
| 3 | EUCTR2015-003291-77-IE (EUCTR) | 03/02/201620160203 | 03/12/201520151203 | A study looking at the safety of the drug GLPG1837 in patients with cystic fibrosis and the G551D mutation A study looking at the safety of the drug GLPG1837in patients with cystic fibrosis and the G551D mut ... | A phase IIa, open label study of multiple doses of GLPG1837 in subjects with cystic fibrosis and the G551D mutation A phase IIa, open label study of multiple doses of GLPG1837in subjects with cystic fibrosis and the ... | Cystic fibrosis with the G551D mutation MedDRA version: 19.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Cystic fibrosis with the G551D mutation MedDRA version: 19.0;Level: PT;Classification code 10011762; ... | Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive nam ... | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 32 | Phase 2 | Czech Republic;Ireland;Australia;Germany;United Kingdom | ||
| 4 | EUCTR2015-003291-77-GB (EUCTR) | 02/02/201620160202 | 03/11/201520151103 | A study looking at the safety of the drug GLPG1837 in patients with cystic fibrosis and the G551D mutation A study looking at the safety of the drug GLPG1837in patients with cystic fibrosis and the G551D mut ... | A phase IIa, open label study of multiple doses of GLPG1837 in subjects with cystic fibrosis and the G551D mutation A phase IIa, open label study of multiple doses of GLPG1837in subjects with cystic fibrosis and the ... | Cystic fibrosis with the G551D mutation MedDRA version: 18.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Cystic fibrosis with the G551D mutation MedDRA version: 18.1;Level: PT;Classification code 10011762; ... | Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive nam ... | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 32 | Phase 2 | Czech Republic;Ireland;Australia;Germany;United Kingdom | ||
| 5 | NCT02707562 (ClinicalTrials.gov) | February 201620160200 | 22/2/201620160222 | Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) | A Phase IIa, Open-label Study of Multiple Doses of GLPG1837 in Subjects With Cystic Fibrosis and the G551D Mutation A Phase IIa, Open-label Study of Multiple Doses of GLPG1837in Subjects With Cystic Fibrosis and the ... | Cystic Fibrosis | Drug: GLPG1837 dose 1;Drug: GLPG1837 dose 2;Drug: GLPG1837 dose 3 | Galapagos NV | NULL | Completed | 18 Years | N/A | Both | 26 | Phase 2 | Australia;Czech Republic;Germany;Ireland;United Kingdom |
| 6 | EUCTR2015-003291-77-CZ (EUCTR) | 26/01/201620160126 | 16/11/201520151116 | A study looking at the safety of the drug GLPG1837 in patients with cystic fibrosis and the G551D mutation A study looking at the safety of the drug GLPG1837in patients with cystic fibrosis and the G551D mut ... | A phase IIa, open label study of multiple doses of GLPG1837 in subjects with cystic fibrosis and the G551D mutation A phase IIa, open label study of multiple doses of GLPG1837in subjects with cystic fibrosis and the ... | Cystic fibrosis with the G551D mutation MedDRA version: 19.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Cystic fibrosis with the G551D mutation MedDRA version: 19.0;Level: PT;Classification code 10011762; ... | Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive nam ... | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 32 | Phase 2 | Czech Republic;Ireland;Australia;Germany;United Kingdom | ||
| 7 | EUCTR2015-003292-30-BE (EUCTR) | 18/01/201620160118 | 26/11/201520151126 | A study looking at the safety of the drug GLPG1837 in patients with cysticfibrosis and the S1251N mutation A study looking at the safety of the drug GLPG1837in patients with cysticfibrosis and the S1251N mut ... | A phase IIa, open-label study of two doses of GLPG1837 in subjects with cystic fibrosis and the S1251N mutation. A phase IIa, open-label study of two doses of GLPG1837in subjects with cystic fibrosis and the S1251 ... | Cystic fibrosis with the S1251N mutation MedDRA version: 18.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Cystic fibrosis with the S1251N mutation MedDRA version: 18.1;Level: PT;Classification code 10011762 ... | Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive name: GLPG1837 Product Name: GLPG1837 Product Code: GLPG1837 INN or Proposed INN: Not Applicable Other descriptive nam ... | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 6 | Phase 2 | Belgium;Netherlands | ||
| 8 | NCT02690519 (ClinicalTrials.gov) | January 201620160100 | 16/2/201620160216 | Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation) | A Phase IIa, Open-label Study of Two Doses of GLPG1837 in Subjects With Cystic Fibrosis and the S1251N Mutation A Phase IIa, Open-label Study of Two Doses of GLPG1837in Subjects With Cystic Fibrosis and the S1251 ... | Cystic Fibrosis | Drug: GLPG1837 dose 1;Drug: GLPG1837 dose 2 | Galapagos NV | NULL | Completed | 18 Years | N/A | Both | 7 | Phase 2 | Belgium;Netherlands |